400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD
Market cap: $589.0M (2/09/2026)
Price: $11.04
Investor Presentation
Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Reports Third Quarter 2025 Financial Results
Emergent BioSolutions Wins New U.S. Government Contract for ACAM2000® Vaccine
Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Reports Second Quarter 2025 Financial Results
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
S-1
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
S-8 POS
Definitive Revised Proxy Statement
Submission Upload
Correspondence
Confidential Treatment Order